Section 1: The Broken Bargain: How a 20-Year Monopoly Became a 40-Year Rent The patent system’s foundational premise is blunt: […]
Unveiling the Secrets Behind Big Pharma’s Patent Thickets Read Post »
1. Why Prosecution Speed Is a Balance Sheet Issue The 20-year patent term granted under 35 U.S.C. Section 154 is
Patent Prosecution Highway for Drug Patents: The Complete Strategic Playbook Read Post »
Who this is for: Business development leads managing loss-of-exclusivity (LOE) timelines, IP counsel evaluating secondary patent thickets, portfolio managers modeling
Patent Cliff Playbook: Out-License Mature Drug Assets Before LOE Destroys Your P&L Read Post »
The biosimilar first-mover question has a clean theoretical answer and a messy empirical one. Theory says: get to market first,
Biosimilar First-Mover Advantage: What the Adalimumab Market Actually Taught Us Read Post »
Executive Summary Generic pharmaceutical companies face a structural cost squeeze that has worsened since 2016. Teva, Mylan, and Sun Pharma
A deep-dive pillar page for pharma/biotech IP teams, R&D leads, and institutional investors. Part 1: The R&D Productivity Crisis —
Why Formulary Management Is Now an IP Discipline The pharmaceutical formulary started its modern life as an administrative cost control
The 80/80 Paradox: What the Numbers Actually Say The U.S. pharmaceutical market runs on a structural contradiction that no other
The United States pharmaceutical market operates within a network of opaque intermediaries that disconnect manufacturing costs from patient expenditures. Billionaire
Dunking on the Pharma Industry: An In-Depth Analysis of Mark Cuban’s War on Drug Prices Read Post »
Sign in or create a free account to read this DrugPatentWatch article
